Allergic Rhinitis Market
The Allergic Rhinitis market is witnessing a period of significant transformation, driven by rising disease prevalence, expanding treatment pipelines, and growing awareness across the seven major markets (7MM) – the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. In 2023, the Allergic Rhinitis Market Size was highest in the US among the 7MM, accounting for approximately USD 3,600 million, which is further expected to increase by 2034. This growth trajectory reflects both the widening patient pool and the arrival of innovative drug candidates that are poised to redefine standards of care.
In 2023, the prevalence of Allergic Rhinitis was highest in Japan among the 7MM, accounting for approximately 65 million cases, which is further expected to increase by 2034. The emerging drug REGN5713-5714-5715 is expected to launch in EU4 and the UK by 2025, and in Japan by 2026 – a development that has the potential to meaningfully reduce the disease burden of Allergic Rhinitis in the forecasted years.
Allergic Rhinitis Overview
Allergic rhinitis is an atopic disease presenting symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. The condition is classified based on triggering allergen – such as seasonal, perennial/year-round, or episodic – as well as frequency of symptoms (intermittent or persistent) and severity (mild, moderate, or severe).
Risk factors for allergic rhinitis include pollens (tree, grass, and weed, including ragweed), indoor allergens such as house dust mites and animal allergens, vegetal and animal proteins, chemicals, antibiotic use, self-reported air pollution, exposure to farm animals (particularly in low- and middle-income countries), exposure to cats and/or dogs, maternal and paternal smoking, and vigorous physical activity in adolescents.
Typical initial symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion, although extra-nasal manifestations such as allergic conjunctivitis, itchy ears and palate, and asthma are also commonly associated. A positive correlation between the clinical history and allergen sensitization is generally sufficient to support diagnosis.
Diagnosis: Allergic rhinitis is often under-recognized due to low public awareness, limited allergist access, and overlapping diagnoses such as the common cold. Diagnosis is largely based on the patient’s medical history, physical examination, and in vivo IgE tests, although in vitro tests have also found their way into routine allergy diagnostics. Polysensitization is frequent, and in vitro IgE assays – particularly those based on allergen components – provide additional useful information by offering the possibility of distinguishing between genuine sensitization and cross-reactivity.
Treatment: The management of Allergic Rhinitis involves allergen avoidance, pharmacotherapy, allergen-specific immunotherapy, or a combination of all three. Pharmacologic options include intranasal corticosteroids (INSs), oral and intranasal antihistamines, intranasal chromones, oral and intranasal decongestants, anticholinergic agents, and antileukotrienes. The Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines note that INSs are a highly effective first-line treatment for moderate/severe or persistent Allergic Rhinitis due to their strong anti-inflammatory properties – particularly effective in controlling nasal congestion.
Allergic Rhinitis Epidemiology
The Allergic Rhinitis market research conducted by DelveInsight uses a patient-based model, with epidemiology segmented by prevalent cases, diagnosed prevalent cases, severity-specific cases, age-specific cases, and allergen-specific sensitivity – covering the 7MM from 2020 to 2034.
Key epidemiological findings include:
- The estimated total diagnosed prevalent cases of Allergic Rhinitis in the 7MM were nearly 90 million in 2023
- Japan accounted for the highest total diagnosed prevalent cases at approximately 26 million (~30% of 7MM) in 2023
- Among European countries, Germany had the highest diagnosed prevalent cases (~10 million), followed by the United Kingdom (~9 million); Spain had the lowest (~5 million cases)
- In 2023, approximately 20% of cases across the 7MM were classified as mild, 60% as moderate, and 20% as severe
- In the age-specific breakdown, the 18–59 years group had the highest cases (~60 million), followed by those aged 60 and above, 10–17 years, and 0–10 years
- Allergen-specific diagnosed prevalent cases were highest for grass pollen, followed by tree pollen, mites, weed pollen, animal dander, and fungal spores
Allergic Rhinitis Marketed Drugs
- RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray) – Glenmark Pharmaceuticals Inc.
RYALTRIS is a metered, fixed-dose, aqueous suspension prescription nasal spray approved by the FDA for treating symptoms associated with Seasonal Allergic Rhinitis. Each unit contains 665 mcg of olopatadine hydrochloride (a histamine-1 receptor inhibitor) and 25 mcg of mometasone furoate (a corticosteroid). In January 2022, it received US FDA approval for adults and pediatric patients 12 years and older. In August 2021, Glenmark Pharmaceuticals received marketing approval for RYALTRIS across 13 countries in the European Union and the UK.
Emerging Allergic Rhinitis Drugs
- REGN5713-5714-5715 – Regeneron Pharmaceuticals
REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Bet v1, the primary allergen responsible for birch pollen allergies. The three mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron’s VelocImmune platform and together provided maximal inhibition of Bet v1 binding to human polyclonal IgE. The combination is currently in Phase III of clinical development.
- Grass MATA MPL – Allergy Therapeutics
Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids, combined with monophosphoryl lipid-A (MPL) as an adjuvant. It is being developed as a pre-seasonal subcutaneous immunotherapy product for Allergic Rhinitis and/or rhinoconjunctivitis. In November 2023, Allergy Therapeutics completed its Phase III study evaluating efficacy and safety in subjects with seasonal allergic rhinitis induced by grass pollen.
Key Companies in the Allergic Rhinitis Market
Key companies active in different phases of developing Allergic Rhinitis therapies include Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Abdi Ibrahim Pharmaceuticals, Inmunotek, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, and others.
Recent Developments:
- In November 2023, Allergy Therapeutics completed its Phase III study for PQ Grass in patients with seasonal allergic rhinitis and/or rhinoconjunctivitis caused by grass pollen
- REGN5713-5714-5715 by Regeneron Pharmaceuticals is advancing in Phase III trials targeting birch pollen allergic rhinitis, with anticipated launches in EU4 and the UK by 2025 and Japan by 2026
- In January 2022, RYALTRIS received US FDA approval for seasonal allergic rhinitis, expanding Glenmark’s global footprint in the market
- In August 2021, Glenmark received marketing authorization for RYALTRIS across 13 EU countries and the UK, reflecting accelerating approvals across geographies
Conclusion
The Allergic Rhinitis market insight paints a compelling picture of a therapeutic area on the cusp of meaningful advancement. With the United States anchoring market revenues at approximately USD 3,600 million in 2023, and Japan leading in diagnosed patient volume, the burden of Allergic Rhinitis is both substantial and well-documented. The dual challenge of managing both perennial and seasonal forms of the disease – across pediatric and adult populations – continues to push the research agenda forward. The Allergic Rhinitis market trends indicate a clear shift toward biologics and monoclonal antibody therapies, with REGN5713-5714-5715 poised to become a landmark treatment upon approval. Meanwhile, immunotherapy approaches such as Grass MATA MPL signal a continued industry commitment to disease modification rather than symptom management alone. As the pipeline matures and the competitive landscape intensifies, the Allergic Rhinitis market is well-positioned for sustained growth through 2034 – creating substantial opportunity for stakeholders across the pharmaceutical, biotech, and diagnostics sectors.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
